The finding

A German cohort (n = 30+ SMA infants treated with nusinersen or onasemnogene abeparvovec) shows that swallowing development remains delayed compared with healthy peers, with the delay proportional to SMN2 copy number. Source: SMA News Today 2026-03-23.

Why it matters

The "early-treatment cure" narrative has held the field for three years. This data suggests that bulbar (swallowing) function is an independent failure mode not fully rescued by SMN restoration, at least not within the first months of life. That is consistent with the 2026 SMA Congress theme that SMA is systemic, not just motor-neuron.

Implications:

• Swallowing should be tracked as a distinct outcome in ongoing SMN-therapy cohorts
• There may be a druggable SMN-independent node in the brainstem / vagal nucleus pathway
• Combination therapies (SMN + adjunct) are justified for early-treated infants, not just for late-treated